Product Progress VectorLogics is focusing on three product areas utilizing our patented targeted adenovector technology:  Cancer Virotherapy Cancer Vaccines Prophylactic & Therapeutic Vaccines VectorLogics' product candidates, through their specificity and efficiency, have the potential to address, and correct, some of the major limitations of gold standard cancer therapeutics - mainly, lack of efficiency to specific cancer cells and toxicity to normal cells. VectorLogics is focusing on two product areas utilizing our IBDV technology:  Viral hepatitis Hepatocellular carcinoma Superinfection therapy combined with oral delivery of VLI's novel drug candidate has the potential to treat chronic HBV and HCV hepatitis resistant to conventional therapies. VLI is also developing a genetically engineered vector platform for the adjuvant treatment of advanced hepatocellular carcinoma (HCC). Vectorlogics' Pipeline